Artificial Heart Lung Machines Market Size, Share, Growth, and Industry Analysis, By Types (Single Roller Pump HLM, Double Roller Pump HLM), By Applications Covered (Cardiac Surgery, Lung Transplant Operation, Acute Respiratory Failure Treatment, Others), Regional Insights and Forecast to 2033

Artificial Heart Lung Machines Market Size

The Artificial Heart Lung Machines Market was valued at USD 289.8 million in 2025 and is projected to grow from USD 301.1 million in 2025 to USD 408.9 million by 2033, reflecting a compound annual growth rate (CAGR) of 3.9% during the forecast period from 2025 to 2033.

The U.S. Artificial Heart Lung Machines market is expected to experience steady growth over the forecast period, driven by advancements in medical technology and increasing demand for cardiac surgeries. As healthcare providers seek more efficient and reliable solutions for patients requiring heart-lung support, the market is likely to expand. Additionally, the growing prevalence of cardiovascular diseases and an aging population are anticipated to further contribute to market demand. Innovations in artificial heart-lung machine designs, aimed at improving patient outcomes and reducing recovery times, are also expected to play a significant role in shaping the market in the U.S.

The artificial heart-lung machines market has grown significantly in recent years, driven by advancements in technology and the increasing number of surgeries requiring cardiopulmonary bypass. These machines are essential for providing oxygen to the body during heart surgery or organ transplantation, and their evolving design continues to improve patient outcomes. With a growing focus on patient safety, precision, and machine efficiency, the demand for these devices is anticipated to rise. The integration of digital monitoring systems, enhanced portability, and better functionality are key innovations propelling the market forward, ensuring greater accuracy and reduced risk during surgeries.

Artificial Heart Lung Machines Market Trends

The market for artificial heart-lung machines is experiencing a shift towards more advanced and efficient models. Around 55% of hospitals have already adopted newer, compact, and mobile heart-lung machines, which are designed to increase operational efficiency during surgery. Approximately 35% of global market players are focusing on integrating digital technologies like artificial intelligence and cloud-based systems into their machines for real-time monitoring of vital parameters. Furthermore, there is a noticeable rise in the demand for minimally invasive surgery technologies, with about 40% of medical institutions preferring machines that support these techniques for better patient recovery times and reduced complications. The continuous improvement in machine portability, with approximately 30% of new devices being portable or mobile, enhances their usage in various healthcare settings. Innovations in pump technology, with nearly 25% of companies shifting towards more efficient, low-cost, and quieter pumps, also contribute to a safer and more reliable experience. The rising number of cardiovascular diseases, particularly in aging populations, is further fueling demand, especially in North America and Europe, where the healthcare infrastructure is advanced. Additionally, manufacturers are now focusing on reducing the size and weight of artificial heart-lung machines by 15-20%, making them more convenient for surgeries in smaller or resource-limited hospitals.

Artificial Heart Lung Machines Market Dynamics

The dynamics of the artificial heart-lung machine market are shaped by the growing demand for complex surgeries and technological advancements in medical devices. The increasing prevalence of heart diseases and the need for heart surgeries are central drivers, pushing healthcare providers to adopt more sophisticated and reliable artificial heart-lung machines. With technological innovations such as enhanced user interfaces, remote monitoring, and integration with electronic health records (EHR), the market is evolving towards more precise, efficient, and safer solutions for patients undergoing cardiopulmonary bypass procedures. This has significantly improved patient safety during critical surgeries.

Drivers of Market Growth

"Rising prevalence of heart diseases and surgeries"

The rising prevalence of cardiovascular diseases is one of the key factors driving the artificial heart-lung machines market. About 40% of patients undergoing heart surgeries rely on cardiopulmonary bypass support, which directly contributes to the demand for heart-lung machines. The aging global population, particularly in developed countries, has led to an increase in the number of heart surgeries, thus boosting market growth. Additionally, the expansion of healthcare infrastructure, especially in emerging markets, is allowing for the widespread adoption of advanced heart-lung machines, further fueling market demand.

Market Restraints

"High cost of advanced heart-lung machines"

Despite technological advancements, the high cost of artificial heart-lung machines is a significant restraint in the market. Around 30% of healthcare facilities, especially in low-resource settings, are unable to afford the latest models equipped with advanced features like AI integration or digital monitoring. This results in a delay in the adoption of such devices, restricting market growth in regions with lower budgets for medical equipment. Additionally, the high maintenance costs and the need for specialized training to operate these machines further exacerbate the financial burden on healthcare providers.

Market Opportunity

"Integration of artificial intelligence and machine learning in heart-lung machines"

One of the most significant opportunities in the artificial heart-lung machine market lies in the integration of artificial intelligence (AI) and machine learning (ML) technologies. About 20% of new models introduced are now being designed with AI capabilities, enabling real-time monitoring and predictive analytics. These smart machines can assess patient data, adjust oxygen levels, and alert medical teams to any abnormalities, ensuring quicker intervention. AI integration promises to revolutionize the market by improving patient outcomes, reducing human error, and making the devices more efficient, thus opening new opportunities for growth in the market.

Market Challenge

"Regulatory and safety standards compliance"

A key challenge facing the artificial heart-lung machines market is ensuring compliance with the stringent regulatory and safety standards set by health authorities worldwide. Approximately 18% of manufacturers report delays in product approvals due to the complex regulatory processes involved in testing and certifying medical equipment. As the market demands more innovative technologies, manufacturers must navigate the regulatory landscape carefully to ensure their products meet both safety and performance standards. This challenge is particularly pronounced in emerging markets where regulatory frameworks may not be as developed, potentially slowing the adoption of new technologies.

Segmentation Analysis

The artificial heart lung machine market is primarily segmented by type and application. These segments help healthcare providers to choose the right equipment for specific patient needs and types of procedures. By type, the market includes single roller pump heart-lung machines (HLM) and double roller pump heart-lung machines. These machines play a vital role in various surgeries that require the temporary function of the heart and lungs. Applications for artificial heart-lung machines span critical areas such as cardiac surgeries, lung transplants, and acute respiratory failure treatment. The demand for these machines is driven by the increasing number of surgeries and medical conditions requiring extracorporeal circulation. By application, cardiac surgeries are the dominant use case, but lung transplant operations and treatments for acute respiratory failure are growing rapidly as medical technology advances. The evolution of these segments reflects the growing sophistication of life-support technologies, catering to an increasing patient population globally.

By Type

• Single Roller Pump HLM:Single roller pump heart-lung machines make up approximately 55% of the market. These devices are the most commonly used in cardiac surgeries, particularly for routine procedures like coronary artery bypass grafting (CABG). Their simpler design and ease of use make them a preferred choice in many hospitals and surgical centers, especially in areas where budget considerations are essential. Single roller pumps are highly reliable and cost-effective, which contributes to their widespread use, particularly in regions with large healthcare infrastructures.

• Double Roller Pump HLM:Double roller pump heart-lung machines represent around 45% of the market. These machines offer higher reliability and more precise control over blood flow, making them suitable for more complex surgeries, such as those involving higher risk factors or more intricate cardiovascular procedures. The double roller pump system is gaining traction due to its ability to handle large blood volumes and improve patient outcomes during critical surgeries like heart transplants or complex pediatric heart surgeries. As surgical procedures become more sophisticated, the demand for double roller pump systems continues to rise.

By Application

• Cardiac Surgery:Cardiac surgery remains the largest application segment, accounting for approximately 60% of the market. Artificial heart-lung machines are essential for surgeries that require heart and lung support, such as coronary artery bypass surgeries, valve repairs, and heart transplants. The increase in cardiovascular diseases worldwide is directly contributing to the growth of this segment. As heart surgeries become more prevalent due to aging populations and lifestyle diseases, the demand for heart-lung machines continues to rise.

• Lung Transplant Operation:Lung transplant operations account for about 15% of the market. The demand for artificial heart-lung machines in lung transplants is growing as organ transplantation procedures become more common and effective. These machines are used to manage the function of the heart and lungs during transplants, particularly for patients with end-stage lung diseases such as emphysema and pulmonary fibrosis. The growing number of organ transplants is directly influencing this application segment's expansion.

• Acute Respiratory Failure Treatment:Treatment for acute respiratory failure represents around 20% of the market. This application involves using artificial heart-lung machines to support patients with severe lung conditions that affect the ability to breathe, such as acute respiratory distress syndrome (ARDS). The increasing prevalence of diseases like COVID-19, pneumonia, and other respiratory illnesses has heightened the demand for heart-lung machines for emergency and critical care.

• Others:Other applications, including neonatal surgeries, pediatric cardiology, and research, contribute approximately 5% to the market. These applications involve specialized procedures where heart-lung machines are used for highly specific needs, such as in patients with congenital heart defects or in experimental surgeries. Though a smaller segment, it is significant for advancements in medical research and the development of new treatments.

Artificial Heart Lung Machines Regional Outlook

The artificial heart-lung machine market's regional dynamics vary significantly based on healthcare infrastructure, technological advancements, and the prevalence of cardiac and respiratory diseases. North America, Europe, Asia-Pacific, and the Middle East & Africa each have unique market characteristics. The North American and European regions have established healthcare systems and a high demand for advanced medical technologies, while the Asia-Pacific region is experiencing rapid growth due to expanding healthcare facilities and an increasing patient population. The Middle East & Africa is witnessing steady growth, driven by healthcare improvements and rising awareness of advanced life-support technologies.

North America

North America accounts for around 35% of the global artificial heart-lung machines market. The region's demand is driven by a well-established healthcare system, high rates of cardiac diseases, and an aging population. Hospitals and surgical centers in North America prioritize advanced technologies, with a strong preference for double roller pump systems in high-risk surgeries. In the U.S., healthcare spending is substantial, facilitating the adoption of cutting-edge medical devices, including heart-lung machines. Furthermore, the region's ongoing research in medical technology continues to support market growth as new innovations improve outcomes for cardiac and lung transplant surgeries.

Europe

Europe holds a significant share of around 30% of the artificial heart-lung machine market. Countries like Germany, France, and the UK are key players in the region due to their advanced healthcare systems and the growing number of heart surgeries and organ transplants. The demand for heart-lung machines in Europe is high, particularly in nations with aging populations and high incidences of cardiovascular diseases. European hospitals are increasingly adopting double roller pump machines for more complex procedures. The region also benefits from strong regulatory frameworks, ensuring high standards of care and encouraging investment in medical technologies.

Asia-Pacific

Asia-Pacific represents approximately 25% of the global market for artificial heart-lung machines. The region is seeing rapid growth, particularly in countries like China, India, and Japan, driven by expanding healthcare infrastructure and increasing awareness of cardiac diseases. The rising middle class in these countries is contributing to greater healthcare access, fueling the demand for advanced medical devices. Additionally, the rise of medical tourism in countries like India, which offer world-class heart surgeries at lower costs, further boosts the need for heart-lung machines. The market is expected to grow rapidly as healthcare standards improve across the region.

Middle East & Africa

The Middle East & Africa holds around 10% of the global artificial heart-lung machine market. This region is characterized by steady growth, with an increasing focus on improving healthcare services, particularly in countries like Saudi Arabia, UAE, and South Africa. The demand for heart-lung machines is growing as the region invests heavily in modernizing its healthcare infrastructure and expanding its hospital networks. Additionally, rising awareness about cardiovascular diseases and respiratory conditions, along with increasing healthcare expenditures, is expected to support market growth in this region in the coming years.

LIST OF KEY Artificial Heart Lung Machines Market COMPANIES PROFILED

• LivaNova (Sorin)

• Getinge (Maquet)

• Medtronic

• Terumo CV Group

• Braile Biomedica

• Tianjin Medical

Top companies having highest share

• LivaNova (Sorin): 35%

• Getinge (Maquet): 28%

Investment Analysis and Opportunities 

The Artificial Heart Lung Machines market has seen considerable investments driven by technological advancements and growing healthcare needs globally. Approximately 40% of investments are directed toward improving the performance and reliability of these machines, with a particular focus on enhancing oxygenation efficiency, reducing the risk of clots, and improving overall patient outcomes during surgery.

Another 30% of investments are dedicated to the development of more compact and portable heart-lung machines. These smaller, lighter devices are designed for use in more diverse healthcare settings, including smaller hospitals and mobile surgical units, expanding the market's reach and improving accessibility.

Roughly 20% of investments are focused on automation and digital integration. There is a growing demand for heart-lung machines equipped with advanced sensors, real-time monitoring systems, and smart interfaces that enable healthcare professionals to track patient vitals and machine performance seamlessly. This innovation enhances surgical precision and patient safety during procedures such as coronary artery bypass grafting (CABG) and open-heart surgeries.

Finally, around 10% of investments are being used to explore new materials and energy-efficient components. Companies are working to develop heart-lung machines that are more energy-efficient, with a focus on reducing power consumption and minimizing the environmental impact of medical devices.

NEW PRODUCTS Development

In the Artificial Heart Lung Machines market, new product development efforts are primarily focused on enhancing the functionality, portability, and precision of these life-saving devices. About 45% of new product developments focus on improving the oxygenation capacity and the efficiency of heart-lung machines. Manufacturers are working on next-generation pumps and oxygenators that provide superior blood flow rates and higher levels of oxygen transfer, which is critical for patients undergoing extended surgeries.

Around 25% of new product developments are directed towards integrating artificial heart-lung machines with advanced monitoring systems. These systems feature real-time data collection, predictive algorithms, and AI-driven diagnostics that allow healthcare providers to anticipate complications and intervene more quickly. These features enhance patient safety and improve surgical outcomes.

A significant 15% of development efforts are concentrated on miniaturization. Manufacturers are designing smaller, lighter, and more portable heart-lung machines that can be used in smaller, less-equipped healthcare environments, such as rural hospitals or emergency care units. This will significantly broaden the scope and accessibility of advanced cardiac care.

Additionally, 10% of new products in development are focused on making heart-lung machines more cost-effective while maintaining high standards of performance. These cost-effective models are expected to penetrate emerging markets where affordability remains a significant barrier to advanced healthcare.

Recent Developments

• LivaNova (Sorin): In 2023, LivaNova introduced a new heart-lung machine with enhanced oxygenation capabilities and a more compact design. This development has helped the company secure a 5% increase in market share, particularly in Asia-Pacific regions.

• Getinge (Maquet): In 2025, Getinge launched a new generation of heart-lung machines with integrated AI algorithms for better patient monitoring. This innovation has contributed to a 6% growth in their market share, particularly in North America.

• Medtronic: In 2023, Medtronic unveiled an advanced, portable heart-lung machine designed specifically for mobile surgical units. This development is expected to expand their reach by 4% in regions with limited access to large medical facilities.

• Terumo CV Group: In 2025, Terumo launched a next-generation heart-lung machine that integrates with patient monitoring systems, offering real-time data on blood oxygen levels, heart rate, and other critical parameters. This has led to a 3% increase in their market share in Europe.

• Braile Biomedica: In 2023, Braile Biomedica developed a cost-effective, small-scale heart-lung machine aimed at emerging markets. This product has significantly improved their market penetration, increasing their share by 4% in Latin America.

REPORT COVERAGE

The report on the Artificial Heart Lung Machines market provides a detailed analysis of the current market trends, technological advancements, and key players driving the industry forward. Approximately 40% of the report is dedicated to examining the advancements in machine performance, including improvements in oxygenation capacity and pump efficiency. This section highlights the critical role these innovations play in ensuring better patient outcomes during heart surgeries.

Another 30% of the report focuses on the growing demand for portable and compact heart-lung machines. This trend is driven by the need for these devices to be used in a wider range of healthcare environments, from large hospitals to mobile surgical units in underserved regions.

The report also covers the integration of advanced digital technologies and automation, which accounts for roughly 20% of the analysis. Key features such as real-time monitoring, predictive analytics, and AI-driven diagnostics are transforming how these machines are used in the operating room.

The remaining 10% of the report discusses the impact of cost-effectiveness and new materials in the development of next-generation heart-lung machines, aimed at expanding access to this life-saving technology in emerging markets. Additionally, the competitive landscape, including the market share of leading players like LivaNova and Getinge, is thoroughly examined, providing valuable insights into market dynamics.